ibuprofen 400 mg capsule moi
apotex inc. - ibuprofenum - capsule moi - 400 mg
phorcal unguent 3 mcg/g
kusum healthcare pvt.ltd - calcitriolum - unguent - 3 mcg/g
fexeric
akebia europe limited - complexul de coordonare a citratului feric - hyperphosphatemia; renal dialysis - medicamente pentru tratamentul hiperkaliemiei și hiperfosfatemiei - fexeric este indicat pentru controlul hyperphosphataemia la pacienţii adulţi cu boli cronice de rinichi (ckd).
candesartan hidroclorotiazida aurobindo 8 mg/12,5 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 8mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
candesartan hidroclorotiazida aurobindo 16 mg/12,5 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 16mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
candesartan hidroclorotiazida aurobindo 32 mg/12,5 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 32mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
candesartan hidroclorotiazida aurobindo 32 mg/25 mg
apl swift services (malta) limited - malta - combinatii (candesartanum cilexetil+hct) - compr. - 32mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic
candesartan aurobindo 8 mg
apl swift services (malta) limited - malta - candesartanum cilexetil - compr. - 8mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
candesartan aurobindo 16 mg
apl swift services (malta) limited - malta - candesartanum cilexetil - compr. - 16mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - toate celelalte produse terapeutice - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.